As the COVID-19 pandemic continues with many thousands of new infections reported each day, there is a need for widely applicable surveillance testing to gain a better understanding of infection rates, especially the number of infections in people with mild or no symptoms, who can still be carriers.
In a new study, researchers found developed a new kind of antibody test—a simplified experimental assay that could be ramped up to test thousands of blood samples at labs that do not have the resources of commercial labs and large academic medical centers.
The research was conducted by the UNC School of Medicine scientists and colleagues.
In the study, the researchers created a blood test to pinpoint SARS-CoV-2 antibodies that target one unique piece of the SARS-CoV-2 spike protein.
That piece is called a receptor-binding domain, or RBD.
Their RBD-based antibody test can measure the levels of that domain, which they found to correlate to the levels of the all-important neutralizing antibodies that provide immunity.
The RBD of the spike protein in SARS-CoV-2 is not shared among other known human or animal coronaviruses.
Therefore, antibodies against this domain are likely to be highly specific to SARS-CoV-2, and so these antibodies reveal if an individual has been exposed to the virus that can cause COVID-19.
Indeed, when the researchers tested blood collected from people exposed to other coronaviruses, none had antibodies to the RBD of SARS-CoV-2.
The team says their assay is extremely specific for antibodies to the virus that causes COVID-19, which is not the case for some currently available antibody tests.
The results strongly support the use of RBD-based antibody assays for population-level surveillance and as a correlate of the neutralizing antibody levels in people who have recovered from SARS-CoV-2 infections.
The researchers are now further streamlining our test into an inexpensive assay, so that instead of the test-taking four to five hours to complete, the assay could be completed in about 70 minutes without compromising quality.
The UNC-Chapel Hill researchers have received requests from scientists across the country and around the world for assistance with establishing this new assay within their research laboratories to monitor people for SARS-CoV-2 infection.
One author of the study is Aravinda de Silva, a professor of microbiology and immunology and a member of the UNC Institute for Global Health and Infectious Diseases.
The study is published in Science Immunology.
Copyright © 2020 Knowridge Science Report. All rights reserved.
